Skip to content

Patient experience and advocacy

TL;DR — Fibromyalgia's defining patient experience is a legitimacy battle: two decades of qualitative research show patients disbelieved by clinicians, family, and employers, with stigmatization most intense before diagnosis (Åsbring 2002, PMID 11837367; Sim 2008, PMID 18423826), and physicians themselves ranking FM at the bottom of a 38-disease prestige hierarchy in three surveys spanning 25 years (Album 2017, PMID 28319909). The diagnosis takes on average 2.3 years and 3.7 physicians after presentation (Choy 2010, PMID 20420681), delivers relief that curdles into abandonment when no explanation or pathway follows (Mengshoel 2018, PMID 28762775; Undeland 2007, PMID 18041660), and leaves 22% unable to work while public deservingness rankings place FM claimants below wheelchair users, schizophrenia, and back pain (Geiger 2021, PMID 34295021). Patients' own outcome priorities — fatigue, unrefreshing sleep, cognition, symptom fluctuation — historically outran what trials measured, and drove the OMERACT core-domain reform (Arnold 2008, PMID 18640807; Mease 2009, PMID 19820221). The organizational landscape (NFA, FMA UK, ENFA and ~21 European members, Canadian ME/FM Action Network, Nordic associations) is real but thin and unstable, and — the biggest structural gap — FM has no patient-partnered research infrastructure comparable to what smaller, higher-prestige conditions have built.

1. The lived experience: what the qualitative literature establishes

FM has one of the deepest qualitative literatures of any chronic condition — multiple metasyntheses now sit atop dozens of primary studies (Sim 2008, PMID 18423826; Mengshoel 2018, PMID 28762775; Climent-Sanz 2024, PMID 37965900; Yung 2025, PMID 40093347; full annotated inventory in ../literature/patient-voice/sources.md, thematic synthesis in ../literature/patient-voice/themes.md). Converging findings:

Finding Key evidence
Legitimacy contested pre-diagnosis; symptoms psychologized; veracity/morality questioned Åsbring 2002 (PMID 11837367); invalidation meta-synthesis: Bontempo 2025 (PMID 40310228)
Diagnosis delayed ~2.3 y over ~3.7 physicians; ~1 y pre-presentation delay Choy 2010 (PMID 20420681); journey scoping review: Otón 2024 (PMID 38395498)
Diagnosis = relief then abandonment ("hardly helpful"); validates without explaining Undeland 2007 (PMID 18041660); Mengshoel 2018 (PMID 28762775); Boulton 2019 (PMID 30296924)
Partial biographical disruption; masking; identity re-work; some report illness gains Åsbring 2001 (PMID 11328436); Kengen Traska 2012 (PMID 21323780); Fitzmaurice 2024 (PMID 38247699)
Gendered credibility work (women); delayed recognition, distinct presentation, and under-study of men Werner 2003 (PMID 12927471); Quintner 2020 (PMID 31986200); Kueny 2021 (PMID 33771468); Ruschak 2023 (PMID 36673591)
Boom-bust activity vs pacing as learned discipline Antcliff 2016 (PMID 26385155); Dépelteau 2021 (PMID 34780617); Pearson 2020 (PMID 32452615)
Medication disillusionment → self-management pivot; low adherence mediated by stigma Climent-Sanz 2024 (PMID 37965900); Prikhodkina 2024 (PMID 38284436); Bennett 2007 (PMID 17349056)
Work loss (22% unable; ~59% mean capacity loss in assessed cohort) and benefit battles Choy 2010 (PMID 20420681); Krakov 2021 (PMID 33886454); Lev 2022 (PMID 33043704); Geiger 2021 (PMID 34295021)
Online communities as legitimacy infrastructure — and low-quality-information exposure Berard 2019 (PMID 30066603); Millar 2024 (PMID 38333024); Ozsoy-Unubol 2021 (PMID 33355406); Canatan 2024 (PMID 39156279)
Clinician attitudes are a measurable exposure: skepticism, moralizing, bottom-of-hierarchy prestige Åsbring 2003 (PMID 12821018); Album 2007 (PMID 17850944); Agarwal 2024 (PMID 39093781); Byrne 2023 (PMID 37750736)

Two structural features distinguish FM from most chronic-disease experience literatures. First, the disbelief is bidirectional and institutional: the same skepticism patients report is documented from the clinician side, in physicians' own words (patients characterized as "demanding and medicalising", denied full sick-role access; Åsbring 2003, PMID 12821018) and in the prestige surveys, where FM sat among the lowest-ranked of 38 diseases among Norwegian physicians in 1990, 2002, and 2014 — named first of "the four lowest ranked" across all three rounds (Album 2007, PMID 17850944; Album 2017, PMID 28319909). The stigma follows patients even into other diseases: an FM co-diagnosis in autoimmune rheumatic disease predicts lower trust, lower satisfaction, and documented dismissal (Manavi 2026, PMID 42236570). Second, the diagnosis itself is ambivalent therapy: it is simultaneously the endpoint patients fight years for and — contra the delay-reduction agenda — a label several qualitative studies find delivers little once granted (Undeland 2007, PMID 18041660; Boulton 2019, PMID 30296924; see history-and-nosology for the contested-illness lineage and diagnostic-criteria for the criteria instability that feeds this: Wolfe 2013, PMID 23820862).

2. What patients report that trials underweight

Patient-generated data consistently rank domains that FM trials historically treated as secondary:

  • The patient symptom hierarchy. In the National Fibromyalgia Association's internet survey of 2,596 people with FM, the most common problems were morning stiffness, fatigue, nonrestorative sleep, pain, and concentration/memory difficulty — pain is one item in a five-domain cluster, not the whole disease (Bennett 2007, PMID 17349056). Focus groups convened specifically because existing outcome measures fell short identified pain, sleep disturbance, fatigue, depression, anxiety, and cognitive impairment as the highest-impact domains, plus pervasive social/occupational loss (Arnold 2008, PMID 18640807).
  • This patient input reshaped the trial core set. OMERACT's FM module — built on patient Delphi exercises and focus groups feeding clinician consensus — mandated pain, tenderness, fatigue, patient global, multidimensional function, and sleep disturbance for all FM trials, with dyscognition and depression situational (Mease 2009, PMID 19820221; pooled-trial validation of the core dataset: Choy 2009, PMID 19820222). The measurement mechanics and their limits live in outcomes-and-measurement.
  • Fibrofog remains the under-measured domain with the largest identity payload. Peer-support-group analysis shows cognitive dysfunction driving distrust of one's own mind, social withdrawal, work impairment, and pain-versus-medication-fog tradeoffs — with patients reporting it poorly understood clinically (Millar 2024, PMID 38333024); dyscognition never achieved mandatory core-set status (Mease 2009, PMID 19820221).
  • Symptom fluctuation is an outcome property, not noise. Patients advising intervention design ask for programs and endpoints that accommodate day-to-day fluctuation rather than assume monotonic response (Courel-Ibáñez 2023, PMID 37451740) — a mismatch with fixed-timepoint responder analyses (outcomes-and-measurement, clinical-trials-landscape).
  • Perceived treatment effectiveness diverges from guideline evidence. The NFA survey's respondents rated rest and heat among the most effective modalities, and perceived opioid and benzodiazepine-class drugs as their most effective medications (Bennett 2007, PMID 17349056) — a standing measure of the gap between lived pharmacy and what guidelines endorse (pharmacologic-therapy, guidelines); qualitative syntheses show the disappointment cycle driving a self-management pivot (Climent-Sanz 2024, PMID 37965900; Yung 2025, PMID 40093347).
  • What patients want measured includes the care relationship itself. Consultation-experience synthesis shows being believed and receiving explanation function as outcomes in their own right (Byrne 2023, PMID 37750736); validation/invalidation has measurable psychological sequelae (Bontempo 2025, PMID 40310228).

3. The organization landscape

Full verified directory with access dates: ../literature/patient-voice/organizations.md. Shape of the landscape:

  • United States. The National Fibromyalgia Association (founded 1997) is the historical anchor — education, patient stories, and the field's largest patient survey (Bennett 2007, PMID 17349056). Alongside it: the Fibromyalgia National Health Organization (2017, formerly Support Fibromyalgia Network; group-medical-visit care model) and the Fibromyalgia Care Society of America (2015, NJ; holistic care and provider education). US organizational infrastructure is unstable: renames, dormant sites, and unclear operating status are common (organizations.md, quarantine table).
  • UK & Ireland. Fibromyalgia Action UK runs national helplines — including a dedicated benefits helpline — support groups, and clinician education packs; UK Fibromyalgia is a 20+-year monthly magazine with support-group and doctor directories; Ireland's coverage runs through Chronic Pain Ireland (no verifiable FM-specific national charity).
  • Europe. ENFA (≈2008, Brussels-registered) federates ~21 national associations across 15+ countries and has taken FM into the European Parliament via round tables. National members range from large multi-branch associations (Sweden's Fibromyalgiförbundet, 27 local branches, with its own FM research-grant foundation; Norway's NFF with a research fund and peer-counselor corps; Germany's DFV) to small volunteer groups.
  • Canada. The National ME/FM Action Network (1993) pairs FM with ME/CFS structurally — it spearheaded the Canadian Consensus Criteria process, maintains a research registry and scholarships, and publishes a CPP disability guide.
  • Asia-Pacific & Africa. Fibromyalgia Australia (Bridges & Pathways Institute) descends from a South Australian clinical-research collaboration and foregrounds Medicare/Centrelink/NDIS navigation. New Zealand support runs through complex-chronic-illness and arthritis charities (national portal Healthify's listing). No fetchable organizational site was found for South Africa or India — FM support there runs on platform communities, not incorporated charities (organizations.md).
  • The structural gap. No FM patient organization surfaced this session as running or co-running funded, patient-partnered research infrastructure (registry-based cohort programs, priority-setting partnerships, trial co-design consortia). The nearest approximations: the NFA's published survey (Bennett 2007, PMID 17349056), Sweden's and Norway's grant funds, and Canada's consensus-criteria history (all org-page-verified). Contrast conditions with far smaller populations that have NIHR/PCORI-embedded charities. Given that FM's evidence problems are precisely outcome-selection and trial-design problems (clinical-trials-landscape), this absence is consequential — and is Open question 5.

4. Advocacy history: recognition campaigns and disability recognition

  • May 12. International Awareness Day was created by US advocate Thomas Hennessy Jr., first observed 1993, as an umbrella day for "chronic immunological and neurological diseases" (ME/CFS, FM, MCS, Gulf War syndrome); the date is Florence Nightingale's birthday, chosen for her decades of chronic, contested, FM/ME-like illness (Wikipedia — "International May 12th Awareness Day", https://en.wikipedia.org/wiki/International_May_12th_Awareness_Day, accessed 2026-08-28; National Fibromyalgia Association — "History of Fibromyalgia Awareness Day by the NFA", https://www.fmaware.org/fibromyalgia-awareness-day-history/, accessed 2026-08-28). The NFA operationalized the US National Fibromyalgia Awareness Day from 1998 with a ten-year lawmaker proclamation program (2006 Sacramento "Pledge to Care"; 2008 "Lights of Hope" capitol march) — proclamations continue at municipal level (search-listed 2025 mayoral proclamation video; sources.md §c). Landmark lightings use purple for FM; national associations across Europe run their own May 12 programming (organizations.md). The awareness-day genealogy embeds FM inside the ME/CFS coalition — a fusion that recurs organizationally (Canada, NZ, Australia) and mirrors the shared contested-illness sociology (comorbidities-and-overlap; Åsbring 2002, PMID 11837367).
  • Celebrity disclosure as recognition campaign. Lady Gaga's 2017–2018 disclosures (documentary and press) put "I get so irritated with people who don't believe fibromyalgia is real" into global circulation (Global News — "Lady Gaga on her fight with fibromyalgia", https://globalnews.ca/news/4438236/what-is-fibromyalgia-lady-gaga/, accessed 2026-08-28); Kirsty Young's 2018–2019 departure from BBC Desert Island Discs made FM's invisible incapacitation legible to a UK mass audience (Stylist — "Desert Island Discs: Kirsty Young steps down as host", https://www.stylist.co.uk/people/kirsty-young-desert-island-discs-leaving-illness-fibromyalgia-2018/224455, accessed 2026-08-28).
  • Disability recognition is the second front. Public deservingness rankings place FM claimants below wheelchair users, schizophrenia, and back pain, with "medical legitimation" decisive (Geiger 2021, PMID 34295021); ICF-based coding of Swedish sick-leave certificates finds the existing core sets fit FM work disability imperfectly (Fresk 2024, PMID 39569419). Organizations have institutionalized the response: FMA UK's benefits helpline, the Canadian network's CPP Disability Guide, Fibromyalgia Australia's Centrelink/NDIS navigation (all org-page-verified, organizations.md).
  • Clinician-education campaigns are the third front — FMA UK medical packs, FCSA provider education, Fibromyalgia Australia clinician resources, ENFA's European Parliament work (organizations.md) — running directly against the documented attitude gradient (Agarwal 2024, PMID 39093781; Album 2017, PMID 28319909).
  • Advocacy's ambivalent relationship with the label. Unlike conditions whose campaigns demand earlier diagnosis unambiguously, FM's own literature questions what the diagnosis delivers (Undeland 2007, PMID 18041660) and some clinicians question what the label delivers and how it is applied (Bidari 2018, PMID 30013729; Wolfe 2013, PMID 23820862) — so FM advocacy simultaneously campaigns for recognition of the disease and against reduction of patients to it. This tension is unresolved and structures Open question 1.

Open questions

  1. Does earlier FM diagnosis actually improve outcomes? The delay is well quantified (2.3 y, 3.7 physicians; Choy 2010, PMID 20420681) and delay-reduction tools are emerging (AI screening: Venerito 2026, PMID 42442924), but qualitative evidence says the diagnosis often delivers relief without benefit (Undeland 2007, PMID 18041660; Mengshoel 2018, PMID 28762775). No retrieved study tests whether accelerated diagnosis plus a real post-diagnosis pathway changes trajectories — the intervention target may be the pathway, not the delay.
  2. Can clinician-attitude interventions move the needle on stigma-driven harm? Attitude deficits are measured worldwide (Agarwal 2024, PMID 39093781) and prestige rankings are stable across 25 years (Album 2017, PMID 28319909), yet no retrieved study tests whether clinician-education campaigns (FMA UK packs, ENFA programs) change consultation experience or outcomes (consultation dysfunction documented in Byrne 2023, PMID 37750736).
  3. What would a patient-weighted core outcome set change about the FM evidence base? Patient domains (fatigue, sleep, fibrofog, fluctuation) entered the OMERACT core set unevenly — dyscognition never became mandatory (Mease 2009, PMID 19820221; Arnold 2008, PMID 18640807; Millar 2024, PMID 38333024). Would re-analyzing existing trials on patient-priority endpoints reorder apparent treatment effectiveness? (outcomes-and-measurement)
  4. Are online FM communities net-protective or net-harmful? Support benefits are documented (Berard 2019, PMID 30066603; Merolli 2015, PMID 25616273) and content quality is documented as poor (Ozsoy-Unubol 2021, PMID 33355406; Canatan 2024, PMID 39156279), but no retrieved study measures behavioral or health consequences of exposure — the causal question is open in both directions.
  5. Why has FM produced no patient-partnered research infrastructure, and what would one look like? Given 2%-range prevalence and organizations capable of fielding a 2,596-person survey two decades ago (Bennett 2007, PMID 17349056), the absence of an FM PCORI/NIHR-style collaborative or organization-run registry is anomalous; candidate explanations — prestige gradient (Album 2017, PMID 28319909), benefit-legitimacy politics (Geiger 2021, PMID 34295021), organizational fragility (organizations.md quarantine) — are untested.
  6. Is male FM systematically under-detected, and does the sex ratio partly reflect recognition bias? Men remain under-studied, with delayed recognition and distinct pain presentation reported (Kueny 2021, PMID 33771468; Ruschak 2023, PMID 36673591); criteria-dependent sex-ratio shifts point the same way (diagnostic-criteria; Wolfe 2013, PMID 23820862). Population-based ascertainment studies stratified by criteria set would answer it.
  • overview — where patient experience sits in the whole-condition map.
  • history-and-nosology — the contested-illness history this page's stigma findings live inside.
  • diagnostic-criteria — criteria instability and sex-ratio artifacts behind the diagnosis-journey and gender themes.
  • epidemiology — diagnostic delay, burden, and work-disability denominators.
  • outcomes-and-measurement — the OMERACT core set that patient input built; what trials measure vs. what patients report.
  • pharmacologic-therapy — the real effect sizes behind patient medication disillusionment.
  • non-pharmacologic-therapy — exercise/education/self-management programs patients describe learning to live by.
  • guidelines — guideline recommendations vs. patient-perceived effectiveness.
  • comorbidities-and-overlap — the ME/CFS entanglement that structures advocacy coalitions.
  • clinical-trials-landscape — why FM trials fail; patient-priority endpoints as a candidate fix.

References

  1. Åsbring P, Närvänen AL. Women's experiences of stigma in relation to chronic fatigue syndrome and fibromyalgia. Qual Health Res. 2002;12:148-60. PMID 11837367
  2. Sim J, Madden S. Illness experience in fibromyalgia syndrome: a metasynthesis of qualitative studies. Soc Sci Med. 2008;67:57-67. PMID 18423826
  3. Album D, Johannessen LEF, Rasmussen EB. Stability and change in disease prestige: A comparative analysis of three surveys spanning a quarter of a century. Soc Sci Med. 2017;180:45-51. PMID 28319909
  4. Choy E, et al. A patient survey of the impact of fibromyalgia and the journey to diagnosis. BMC Health Serv Res. 2010;10:102. PMID 20420681
  5. Mengshoel AM, et al. Diagnostic experience of patients with fibromyalgia — a meta-ethnography. Chronic Illn. 2018;14:194-211. PMID 28762775
  6. Undeland M, Malterud K. The fibromyalgia diagnosis: hardly helpful for the patients? A qualitative focus group study. Scand J Prim Health Care. 2007;25:250-5. PMID 18041660
  7. Geiger BB. Disabled but not deserving? The perceived deservingness of disability welfare benefit claimants. J Eur Soc Policy. 2021;31:337-351. PMID 34295021
  8. Arnold LM, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008;73:114-20. PMID 18640807
  9. Mease P, et al. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009;36:2318-29. PMID 19820221
  10. Climent-Sanz C, et al. Fibromyalgia pain management effectiveness from the patient perspective: a qualitative evidence synthesis. Disabil Rehabil. 2024;46:4595-4610. PMID 37965900
  11. Yung K, et al. Exploring patient activation and self-management experiences in adults with fibromyalgia: a qualitative evidence synthesis. Rheumatol Adv Pract. 2025;9:rkaf025. PMID 40093347
  12. Bontempo AC. Ignored, dismissed, and minimized: understanding the harmful consequences of invalidation in health care — a systematic meta-synthesis of qualitative research. Psychol Bull. 2025;151:399-427. PMID 40310228
  13. Otón T, et al. Patient-journey of fibromyalgia patients: a scoping review. Reumatol Clin (Engl Ed). 2024;20:96-103. PMID 38395498
  14. Boulton T. Nothing and everything: fibromyalgia as a diagnosis of exclusion and inclusion. Qual Health Res. 2019;29:809-819. PMID 30296924
  15. Åsbring P. Chronic illness — a disruption in life: identity-transformation among women with chronic fatigue syndrome and fibromyalgia. J Adv Nurs. 2001;34:312-9. PMID 11328436
  16. Kengen Traska T, et al. Strategies used for managing symptoms by women with fibromyalgia. J Clin Nurs. 2012;21:626-35. PMID 21323780
  17. Fitzmaurice BC, et al. The fibromyalgia decomposition phenomenon: a reflexive thematic analysis. Behav Sci (Basel). 2024;14(1). PMID 38247699
  18. Werner A, Malterud K. It is hard work behaving as a credible patient: encounters between women with chronic pain and their doctors. Soc Sci Med. 2003;57:1409-19. PMID 12927471
  19. Quintner J. Why are women with fibromyalgia so stigmatized? Pain Med. 2020;21:882-888. PMID 31986200
  20. Kueny A, et al. Fibromyalgia pain and fatigue symptoms in Spanish and U.S. men. Pain Manag Nurs. 2021;22:423-428. PMID 33771468
  21. Ruschak I, et al. Fibromyalgia syndrome pain in men and women: a scoping review. Healthcare (Basel). 2023;11(2). PMID 36673591
  22. Antcliff D, et al. Exploring patients' opinions of activity pacing and a new activity pacing questionnaire for chronic pain and/or fatigue: a qualitative study. Physiotherapy. 2016;102:300-7. PMID 26385155
  23. Dépelteau A, et al. Occupational adaptation of people living with fibromyalgia: a systematic review and thematic synthesis. Am J Occup Ther. 2021;75(4). PMID 34780617
  24. Pearson J, et al. Fibromyalgia self-management: mapping the behaviour change techniques used in a practice-based programme. Musculoskeletal Care. 2020;18:372-382. PMID 32452615
  25. Prikhodkina M, Melnikov S. Factors that influence medication adherence in women with fibromyalgia: a path analysis. J Clin Nurs. 2024;33:3943-3953. PMID 38284436
  26. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27. PMID 17349056
  27. Krakov A, et al. The correlation between the ACR questionnaire and fitness for work of fibromyalgia patients. Clin Exp Rheumatol. 2021;39 Suppl 130:61-65. PMID 33886454
  28. Lev A, et al. Work volition in women with fibromyalgia: a phenomenological analysis. Disabil Rehabil. 2022;44:2267-2275. PMID 33043704
  29. Berard AA, Smith AP. Post your journey: Instagram as a support community for people with fibromyalgia. Qual Health Res. 2019;29:237-247. PMID 30066603
  30. Millar KA, Crump L, LaChapelle DL. Lived experiences of cognitive dysfunction in fibromyalgia: how patients discuss their experiences and suggestions for patient education. J Patient Exp. 2024;11:23743735241229385. PMID 38333024
  31. Ozsoy-Unubol T, Alanbay-Yagci E. YouTube as a source of information on fibromyalgia. Int J Rheum Dis. 2021;24:197-202. PMID 33355406
  32. Canatan AN. Assessing the quality and reliability of videos related to fibromyalgia on TikTok: a comprehensive analysis. Cureus. 2024;16:e64704. PMID 39156279
  33. Åsbring P, Närvänen AL. Ideal versus reality: physicians perspectives on patients with chronic fatigue syndrome (CFS) and fibromyalgia. Soc Sci Med. 2003;57:711-20. PMID 12821018
  34. Album D, Westin S. Do diseases have a prestige hierarchy? A survey among physicians and medical students. Soc Sci Med. 2008;66:182-8. PMID 17850944
  35. Agarwal A, et al. Physicians' knowledge, attitudes, and practices regarding fibromyalgia: a systematic review and meta-analysis of cross-sectional studies. Medicine (Baltimore). 2024;103:e39109. PMID 39093781
  36. Byrne A, et al. Patient and primary care practitioners' perspectives on consultations for fibromyalgia: a qualitative evidence synthesis. Prim Health Care Res Dev. 2023;24:e58. PMID 37750736
  37. Manavi D, et al. Fibromyalgia in systemic autoimmune rheumatic diseases: a mixed-methods study of patient and clinician perspectives. Rheumatol Int. 2026;46. PMID 42236570
  38. Wolfe F, Walitt B. Culture, science and the changing nature of fibromyalgia. Nat Rev Rheumatol. 2013;9:751-5. PMID 23820862
  39. Choy EH, et al. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol. 2009;36:2330-4. PMID 19820222
  40. Courel-Ibáñez J, et al. Proof of concept of prehabilitation: a combination of education and behavioural change, to promote physical activity in people with fibromyalgia. BMJ Open. 2023;13:e070609. PMID 37451740
  41. Fresk M, et al. Exploring International Classification of Functioning, Disability and Health applicability for coding work-related disability: depression and fibromyalgia in Swedish sick leave certificates. J Rehabil Med. 2024;56:jrm36886. PMID 39569419
  42. Bidari A, Ghavidel-Parsa B, Ghalehbaghi B. Challenges in fibromyalgia diagnosis: from meaning of symptoms to fibromyalgia labeling. Korean J Pain. 2018;31:147-154. PMID 30013729
  43. Merolli M, et al. Patient-reported outcomes and therapeutic affordances of social media: findings from a global online survey of people with chronic pain. J Med Internet Res. 2015;17:e20. PMID 25616273
  44. Venerito V, et al. fAI-BRO: a multimodal AI decision-support system to address diagnostic delay in fibromyalgia syndrome. RMD Open. 2026;12(3). PMID 42442924

Non-journal sources (per CONVENTIONS.md §1): National Fibromyalgia Association — homepage and "History of Fibromyalgia Awareness Day by the NFA" (https://www.fmaware.org/; https://www.fmaware.org/fibromyalgia-awareness-day-history/, accessed 2026-08-28); Fibromyalgia Action UK — homepage (https://www.fmauk.org/, accessed 2026-08-28); ENFA — homepage and Members (https://enfa-europe.eu/; https://www.enfa-europe.eu/members/, accessed 2026-08-28); National ME/FM Action Network — homepage (https://www.mefmaction.com/, accessed 2026-08-28); Fibromyalgia Australia — homepage (https://www.fibromyalgiaaustralia.org.au/, accessed 2026-08-28); Fibromyalgiförbundet — homepage (https://www.fibromyalgi.se/, accessed 2026-08-28); Norges Fibromyalgi Forbund — homepage (https://fibromyalgi.no/, accessed 2026-08-28); Charity Navigator — FCSA profile (https://www.charitynavigator.org/ein/473585746, accessed 2026-08-28); Healthify — "Fibromyalgia support" (https://healthify.nz/support/f/fibromyalgia-support, accessed 2026-08-28); Wikipedia — "International May 12th Awareness Day" (https://en.wikipedia.org/wiki/International_May_12th_Awareness_Day, accessed 2026-08-28); Global News — Lady Gaga fibromyalgia article (https://globalnews.ca/news/4438236/what-is-fibromyalgia-lady-gaga/, accessed 2026-08-28); Stylist — Kirsty Young Desert Island Discs article (https://www.stylist.co.uk/people/kirsty-young-desert-island-discs-leaving-illness-fibromyalgia-2018/224455, accessed 2026-08-28). Full annotated list: ../literature/patient-voice/sources.md.